Nano-X Imaging Shares Fall 19% Following Revenue Miss and Impairment Charge

Nano-X Imaging shares fell 19.3% in premarket trading after a second-quarter 2026 revenue miss and a widening of its GAAP net loss. The results were affected by a noncash impairment charge, which reflects the financial difficulties the company faces while scaling its medical imaging technology.

According to the company's earnings transcript, Nano-X reported revenue of $4.2 million for the quarter. This figure missed the $5.54 million forecast provided by analysts. The company’s GAAP net loss grew to $55.5 million, compared to $14.7 million in the same period a year earlier.

"Commercialization requires close side-by-side coordination with small and medium-sized imaging centers," said Erez Meltzer, Chief Executive Officer of Nano-X Imaging, citing permitting, shielding, construction timelines and workflow integration as hurdles.

Impact of Impairment Charges

The increase in net loss was driven by a $40.7 million noncash impairment charge related to the firm’s AI solutions business. This charge is an accounting adjustment that does not affect immediate cash flow but reflects a downward revision in the carrying value of the segment's assets.

As of June 30, 2026, the company’s liquidity position has tightened. Nano-X reported cash and short-term or restricted deposits of $31.4 million, down from $60.0 million at the end of 2025. This burn rate is a primary concern for investors who are monitoring the company's ability to fund its commercial rollout.

Regulatory Developments and Adoption

Management pointed to recent regulatory progress as a factor for growth. The Centers for Medicare & Medicaid Services (CMS) established code G0680, effective April 1, 2026, which covers the algorithmic analysis of coronary artery calcium and aortic valve calcification.

Management expects this reimbursement code to support commercial adoption of its AI-enabled diagnostic tools. The integration of such codes is a mechanism in the healthcare industry to incentivize providers to adopt new diagnostic technologies by ensuring a path for billing and reimbursement.

Operational Challenges

The company is navigating the transition from technology development to clinical deployment. The hurdles cited by Meltzer, including permitting, shielding, and construction, are logistical barriers for medical hardware companies attempting to install imaging systems in existing, smaller-scale clinical facilities that were not designed to house specialized radiological equipment.